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Summary
There is evidence to suggest that the p120 GAP (GAP), originally described as an inhibitor of
p21-, may also serve as a downstream effector of ras-regulated signal transduction. To determine
whether GAP expression is required for the growth ofhumannormal and leukemic hematopoietic
cells, we used GAP antisense oligodeoxynucleotides to inhibit it and analyzed the effects of this
inhibition on the colony-forming ability of nonadherent, T lymphocyte-depleted mononuclear
cells and of highly purified progenitors (CD34+ MNC) obtained from the bone marrow and
peripheral bloodofhealthy volunteers or chronic myeloid leukemia (CML, bcr-abl-positive) patients.
The acute myelogenous leukemia cell line M07, the Philadelphia' BV173 cell line, and the acute
promyelocytic leukemia NB4 and HL-60 cell lines were similarly examined. GAPantisense treatment
inhibited colony formation from normal myelo-, erythro-, and megakaryopoietic progenitor cells
as well as from CML progenitor cells. Proliferation of M07 (growth factor-dependent) and
BV173 (bcr-abl-dependent) cells, but not that of NB4 and HL-60 (growth factor-independent)
cells, was also inhibited, even though a specific downregulation of GAP was observed in each
cell line, as analyzed by either or both mRNA and protein expression. Stimulation of M07
cells with hematopoietic growth factors increased the expression of GAP as well as the levels
of active GTP-bound p21-. Stimulation of GAP expression was inhibited upon GAP antisense
treatment. Thesedata indicate that p120 GAPis involved in humannormal and leukemic hemopoiesis
and strongly suggest that GAP is not only a p21', 1s inhibitor (signal terminator), but also a
positive signal transducer.
roliferation and differentiation of hematopoietic cells are
regulated by several growth factors that, upon interac-
tion with specific cell surface receptors, activate signal trans-
duction pathways in the cytoplasm and nucleus that affect
the expression ofproliferation- and/or differentiation-associated
genes (1-4). Ligand-activated hematopoietic growth factor
receptors possess intrinsic tyrosine kinase activity or associate
with intracellular tyrosine kinases (4, 5), which in turn phos-
phorylate tyrosine residues of other cytoplasmic proteins (6,
7) in both normal and leukemic cells (8). The IL-2, IL-3,
CSF-1, GM-CSF, epidermal growth factor (EGF)', stem cell
'Abbreviations used in this paper: AML, acute myelogenous leukemia;
A-T-MNC, adherent cells and T lymphocytes; BC, blast crisis; CFU-Meg,
CFU-megakaryocytic; CML, chronic myeloid leukemia; EGF, epidermal
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factor (SCF), and platelet-derived growth factor (PDGF)
receptors (9-13) and several oncogene products with constit-
utively enhanced tyrosine kinase activity Oms, src, abl, bcr-
abl) (13-15) also activate p21- proteins. These proteins are
encoded by the H-, K-, and N-ras genes; they belong to a
family of signal-transducing monomeric proteins with GTP-
binding activity and appear to play a central role in signal
transduction pathways (16). They bind guanine nucleotides
with high affinity and hydrolyze GTP with low catalytic
efficiency. In the GTP-bound form they serve as signal trans-
growth factor; Epo, erythropoietin; FBS, fetal bovine serum; GNRF,
guanine-nucleotide releasing factor; HSP, heat shock protein; MNC,
mononuclearcell; NF-1, neurofibromatosis type 1 protein; PDGF, platelet-
derived growth factor; SCF, stem cell factor.
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mammalian cells, two proteins, p120 GAP andneurofibroma-
tosis type 1 (NF-1) protein, inactivate p21- (18) by inducing
a 100-fold increase of the intrinsically low GTPase activity
of p21"5 which converts GTP-bound active p21'°' to its in-
active GDP-bound form by stimulation GTP-GDPexchange
(17). Several linesofevidence suggestthat, independentlyfrom
itsrole as negative regulator, GAP, butnot NF-1 protein(19),
may also serve as a downstream target for p21'°S. Mutant
forms of p21- that lack effector function also fail to interact
properly with GAP (20), suggesting that p21'°S may regu-
late GAP. Oncogenic forms of p21-, whose GTPase activity
is not upregulated by GAP, bind it with equalor greater affinity
than wild-type p21'°' (21) . Cooperation between GAP and
p21'°' to inhibit coupling between muscarinic receptors and
atrial potassium channels (22), in the RAS-dependent trans-
activation of a polyoma enhancer sequence (23), and in the
activation of mitogen-activated protein (MAP) kinase (24),
have also been reported. Finally, microinjection into oocytes
of neutralizing anti-GAP Abs, or of Abs recognizing, and
peptides corresponding to amino acid sequence of GAP SH3
domain, inhibits transforming v-H-ras p21-induced H1-kinase
(25), andoncogenic H-ras-dependent germinal vesicle break-
down (26), respectively.
We have previously shown that p21'°' plays an important
role in the formation ofnormal and leukemic hematopoietic
colonies (27, and our unpublished observations). To deter-
mine directly whether GAP is a signal transducer important
for the growth of normal and/or malignant hematopoietic
cells, we investigated colony formation and proliferation by
thesecellsunder conditions whereGAPexpression is inhibited.
If GAP acts in hematopoietic cells primarily to inactivate
p21--GTP (activated by hematopoietic growth factors), then
inhibition of GAP expression would be expected to increase
the amount of GTP-bound p21-, to positively regulate
signal transduction, and to increase, or not to affect, hema-
topoieticcolony formation. IfinsteadGAP is not only asignal
terminator but also a signal transducer, inhibition of its ex-
pression may be expected to diminish the number of hema-
topoietic colonies stimulated by a hematopoietic growth
factor(s), regardless of the persistence of p21- in an active
GTP-bound form.
Results of such analyses are reported in this paper.
Materials and Methods
Primary Cells.
￿
Marrows were obtained by aspiration from the
iliac crestofhealthy volunteers afterinformed consent. Light-density
mononuclear cells (MNC), separatedon Histopaque-1077 (Sigma
Chemical Co., St . Louis, MO) density gradient, were enriched for
hematopoieticprogenitors after removing adherent cells and T lym-
phocytes (ATMNC)as described (28). ATMNCwere used as such
or were further enriched for immature hematopoietic progenitor
(CD34') cells using HPCA1 mAb (Becton Dickinson & Co., San
Jose, CA)andDynabead M-450magnetic polystyrene beadscoated
with sheepanti-mouse IgG1(Fc) (Dynal, Oslo,Norway).Theyield
of CD34' cells from ATMNC ranged between 0.5 and3.2% of
thestarting MNCpopulation.MNCfromchronic myeloidleukemia
(CML)-blast crisis (BC) patients were purified similarly. Theyield
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of CD34' cells from primary cells of a CMLBC patient (UPN1)
was 35.2%.
Cell Lines.
￿
M07acute myelogenous leukemia (AML) cells (29)
were grown in IMDM supplemented with 10% fetalbovine serum
(FBS) and IL3, GM-SCF (Genetics Institute, Cambridge, MA),
or SCF (Immunex, Seattle, WA). BV173 and K562 cells with a
t(9;22) chromosomaltranslocation, established from patients with
CML in lymphoid or myeloid BC, respectively (30, 31), NB4
promyelocyticleukemia cells with a t(15;17) chromosomaltranslo-
cation (32),andH1J60(33) promyelocytic leukemia cells, were main-
tained in RPMI 1640 supplemented with 10% FBS.
Oligodeoxynucleotides.
￿
Thesewere synthesized on a DNA syn-
thesizer (model 380B; AppliedBiosystems, Inc., Foster City, CA)
by meansofQ-cyanoethyl-phosphorimidite chemistry. Thesequences
ofGAPantisense andsenseoligodeoxynucleotides are5'-GGC CTC
GGCCGC CATCAT=S' and5'-ATG ATGGCG GCCGAGGCC-
3, respectively. They are complementary (orcorresponding) to 18
nucleotides beginningwith theinitiation codon. GAP mRNA was
detected using theRTPCR technique with a 5' syntheticprimer
(5' TAA GAG AGA GTG ATC GGA GG 3') and a 3' synthetic
primer (5' TGG CTC TGG TGG TGC AAC TG 3'). The
amplification product was detected by hybridization to asynthetic
oligomer included in the amplified segment (5' GGA GAT TAC
TAC ATT GGT GGA AGA CGT TTT TCT TCA CTG 3') en-
compassing nucleotides 706-745ofthepublishedsequence ofhuman
GAP cDNA (34). Computer search (FASTA) indicated that the
GAP antisense oligomer sequence used is not complementary to
any other known gene sequence. 0-actin mRNA was amplified
with primers derived from thepublishedsequence ofhuman (3-actin
anddetected with aprobe corresponding to nucleotides 258-296
(35).
Oligomer Treatment of the Cells.
￿
ATMNC (105), CMLBC
(105
), or CD34' (104) cells were seeded into 24-well culture plates
(Costar Corp., Cambridge, MA) in 0.4 ml IMDM supplemented
with 2% heat-inactivated humanAB serum and Hepesbuffer. Sense
or antisense GAP oligodeoxynucleotides were added at a concen-
trationof 160Fig/ml at thebeginningof culture, andat 80 Wg/ml
18 and40 h later. Appropriate recombinant human growth factors
(50 U/ml IL3, 12.5 ng/ml GM-CSF, 100 ng/ml SCF, and 2 U/ml
erythropoietin [Epo]) were added to the primary cell cultures to-
gether with thethethird dose of oligodeoxynucleotides. IL3 and
GM-CSF were agenerous gift ofGenetics Institute, SCFwaskindly
provided by ImmunexCorp., andEpo wasfrom AmgenInc. (Thou-
sand Oaks, CA). Cellswere further incubated for 16 h and plated
in duplicate in 35-mm petri dishes without washing. Cells of es-
tablished lines (105/ml) were incubated with or without growth
factors, as indicated, in the presence of GAP sense or antisense
oligodeoxynucleotides. Controlgroups were similarly cultured but
without oligomers.
Colony Assays.
￿
Duplicate cultures were prepared in semisolid
methylcellulose medium HCC4230 (Terry Fox Labs., Vancouver,
Canada)or plasma clot (27). Concentrations ofgrowth factorsand
human AB serum during culture were fivefold lower than those
used during theoligodeoxynucleotide treatment.In some cultures,
no growth factorswere added. Forassayofmyeloidcolonies (CFU-
GM), IL3 and GM-CSF alone were used. BFU-E were induced
in thepresence of I1r3 and Epo or SCF plus Epo. Megakaryocytic
colonies (CFU-Meg) were grownin thepresence ofIL6(Genetics
Institute), IL3, and Epo. Cultures were maintained for 10-12 d.
Plates were scanned with an inverted microscope and the number
of colonies (>~50 cells) and clusters (8-40 cells) was determined.
Myeloid colonies were identified by visual inspection and erythroid
colonies were counted after benzidine staining. Immunofluores-cenceanalysis (36) with aglycoprotein IIb/IIIa-specific mAb (37)
identified CFU-Meg.Differentoligodeoxynucleotide preparations,
several bone marrow donors, and CML patients, and the same
batches of human AB serum andHCC4230 medium were used.
Stimulation ofGAPExpression by Growth Factors.
￿
Cells (106/ml
IMDM supplemented with L-glutamine and0.1%BSA) andgrowth
factors were addedat time 0. Cells used formeasurement of GAP
mRNA levels were incubated (101 cells/100 pl/well) in 96-well
culture plates (Falcon, Becton Dickinson&Co., LincolnPark, NJ).
For protein studies, 106 cells/ml were incubated in 35-mm petri
dishes (Nunc, Inc., Naperville, IL). Cells were collected and ana-
lyzed at the indicated times after adding the growth factors.
RT-PCR.
￿
Cells were collected separately from each group and
total RNA wasextracted(38). RNAfrom each groupwasdivided
into twoportions. Onesample wasreversetranscribed using400 U
of Moloneymurine leukemia virus reverse-transcriptase (Bethesda
Research Laboratories, Gaithersburg, MD) and 0.1 Wg of 3'-end
primer of GAP for 1 h at 37°C. The second sample was reverse
transcribed usingthe0-actin 3' primer. ResultingcDNA fragments
were amplifiedwith 5UTaqpolymerase (Perkin ElmerCetus, Nor-
walk, CT) in the presence of 5' primer of either GAP or 0-actin
generating 215- and209-bp fragmentsofGAPand0-actin, respec-
tively, during 50 cycles ofPCR(39). Reaction products were elec-
trophoresed, transferred and hybridized as described (27), using
the appropriate probes.
Immunoprecipitation and Western Blotting. Cells (1-2 x 106)
were solubilized in lysis buffer containing 10 mM Hepes, pH 7.5,
0.15 M NaCl, 10% glycerol, 10 itg/ml each of leupeptin and
aprotinin (Sigma Chemical Co.), 1 mM PMSF, 1 mM Na3VO4,
1% NP-40, and 5 mM EDTA. Postnuclear lysates were immuno-
precipitated for 2 h at 4°C with 5 ttl of anti-human GAP rabbit
serum(UBI, Inc., Lake Placid, NY)coupledto protein ASepharose
(Pharmacia LKB Biotechnology, Piscataway, NJ). Beads were
washed twicewith lysisbuffer andtwicewith 10 mM Hepes, 0.15
mM NaCl,0.2% NP-40solution,andeluted in sample buffer. Im-
munoprecipitated proteins or total cell lysates were separated on
7.5% SDS-PAGE and transferred to nitrocellulose (MCI, West-
boro, MA). Filters were blocked with 0.5% gelatin in TBS and
incubated with anti-human GAP rabbit serum, anti-human heat
shockprotein (HSP 72/73) murine monoclonal IgG2a(Oncogene
Science Inc., Uniondale, NY), or anti-abl antiserum(40) overnight
at 4°C. Filters were washed five timeswith 0.25% Tween, 0.25%
Colonies Inducer
￿
Control
CFU-GM
￿
IL-3
￿
221.3 t 14.4"
GM-CSF
￿
238.8 t 42.3
BFU-E
￿
IL-3 + Epo
￿
156.0 t 24.8
SCF + Epo
￿
36.8 t 6.8
CPU-Meg
￿
IL-6 + IL-3 + Epo
￿
54.5 t 13.2
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NP-40 in TBS buffer. Proteins in the filters were detected using
"II-Protein A (ICN Biomedicals, Costa Mesa, CA) or horseradish-
peroxidase (HRP)-labeled anti-rabbit sera andenhanced chemilu-
minescence (Amersham Corp., Arlington Heights, IL).
Determination of GTP-bound p2'RAS.
￿
Cells (0.5 x 106/ml)
were maintained for18 hat 37°Cin serum- andgrowth factor-free
medium (IMDM supplemented with 0.5% dialyzed BSA and
L-glutamine), washed, resuspended in phosphate-free medium, and
labeled with 32P-orthophosphate (NEN Research Products,
DuPont, Boston, MA) for3 hat 37°C. Levels ofGTP/GDP-bound
p21- were determined as described (41) in 10' cells stimulated or
notwith IL3 (10U/ml in IMDM plus 0.1%BSAandL-glutamine).
Assay of p120 GAP Activity. Serum-starved M07 cells
(10'/sample) were treated with IL-3 for theindicated times andas-
sayed for GAP activity usingpurified p21- (generous gift of Dr.
F. McCormick, Onyx Pharmaceuticals, Richmond, CA) bound
to a-[32P]GTP as described (41). As indicated, GTPase promoting
activity was also examined afterimmunoprecipitation ofp120 GAP
with anti-GAP serumor in thepresence ofn-dodecyl-(3-D-mannoside
(1 mM)whichspecifically inhibits theGTPase stimulating activity
of NF-1 protein (42).
Results
Effect ofGAPAntisense Oligodeoxynucleotideson Normal He-
matopoietic Colony Formation. A-T-MNC were exposed to
GAP oligodeoxynucleotides (160 + 80 + 80 jLg/ml) and
plated under optimal culture conditions for the growth of
specific progenitor cell subsets. CFU-GM were grown in the
presence of IL3 or GM-CSF. BFU-E were expanded with
IL-3 + Epo or SCF + Epo. CFU-Meg growingin thepres-
ence of IL-6 + IL-3 + Epo were identified by mAb im-
munofluorescence staining. As compared to controls, treat-
ment with sense oligodeoxynucleotides did not reduce
significantly the number of colonies derived from CFU-GM
progenitors in thepresence of IL-3 or GM-CSF (16.8 or 9.6%
inhibition), from BFU-Eprogenitors in the presence ofIL-3
+ Epo or SCF + Epo (3.8 or 7.6% inhibition), or CFU-
Meg progenitors (4.6% inhibition) (Table 1). By contrast,
GAPantisense treatment caused significant inhibition ofcolony
Table 1.
￿
Effect of GAP Sense and Antisense Oligodeoxynucleotides on In Vitro Colony Formationfrom Normal A-T-MNC
Number of colonies/plate
Sense
￿
Antisense
￿
Percent inhibition
184.1 ± 32.0
￿
93.9 ± 17.1
￿
49.0 (p <0.001)t
215.8 ± 35.3
￿
61.3 ± 20.8
￿
71 .6 (p <0.001)
150.0 t 8.0
￿
72.5 ± 6.9
￿
51 .7 (p <0.001)
39 .6 ± 6.8
￿
11.7 t 6.2
￿
70.5 (p <0.001)
52.0 ± 10.5
￿
19.2 t 9.7
￿
63.1 (p <0.001)
Values are mean ± SD from duplicate cultures from six to eight separate experiments from two to four different donors.
t Inhibition of colony formation by GAP antisense oligodeoxynucleotides in comparison with sense-treated groups. In parentheses, statistical sig-
nificance (Student's t test).formation by CFU-GM (49.0-71.6%),BFU-E (51.7-70.5%),
and CFU-Meg (63.1%) as compared to sense-treated groups.
The inhibitory effect was weak at lower concentration of GAP
antisense oligodeoxynucleotides (80 + 40 + 40 p,g/ml), and
undetectable at the lowest concentration used (40 + 20 +
20 Ftg/ml).
To analyze the effect of GAP antisense oligodeoxynucleo-
tides on the growth of more homogeneous, less mature popu-
lations of hematopoietic progenitors, colony assays were
performed using CD34+ MNC isolated from A-T-MNC
(Table 2). Treatment of cells with sense oligodeoxynucleo-
tides (160 + 80 + 80 jig/ml) inhibited colony growth stimu-
lated with IL-3, GM-CSF, IL-3 + Epo, SCF + Epo, or
IL-6 + IL-3 + Epo by only 14.3, 16.1, 7.7, 3.0, and 11.1%
as compared with untreated cultures. By contrast, GAP an-
tisense oligodeoxynucleotide treatment efficiently decreased
the number of CFU-GM colonies induced by IL-3 or GM-
CSF (56.5 or 51.1% inhibition, respectively), BFU-E colo-
nies induced by IL-3 + Epo or SCF + Epo (67.5 or 43.1%
inhibition), and CFU-Meg colonies induced by IL-3, IL-6,
and Epo (59.6% inhibition) as compared with values obtained
with sense oligodeoxynucleotide treatment (Table 2).
Effect of GAP Antisense Oligodeoxynucleotides on Prolifera-
tion of Growth Factor-dependent (MO7) or -independent (NB4
and HL-60) Cell Lines. To analyze whether only growth
factor-dependent or also growth factor-independent prolifer-
ation of hematopoietic cells is related to GAP expression,
similar experiments were performed on the M07 cell line,
dependent on IL-3, GM-CSF or SCF for proliferation, and
on the growth factor-independent NB4 and HL-60promye-
locytic cell lines. GAP mRNA expression, as detected by RT-
PCR on RNA extracted from each cell type 72 h after the
first dose of oligodeoxynucleotide was added, was equally
downregulated in the presence of GAP antisense, but not GAP
sense, in all three cell lines (Fig. 1, A-E) . The number of
viable M07 cells after 4, 6, and 8 d of culture with GAP
Table 2.
￿
Effect of GAP Sense and Antisense Oligodeoxynucleotides on In Vitro Colony Formationfrom Normal Bone Marrow
CD34+ MNC
Values are mean ± SD from duplicate cultures from six to eight separate experiments from two to four different donors.
t Inhibition of colony formation by GAP antisense oligodeoxynucleotides in comparison with sense-treated groups. In parentheses, statistical sig-
nificance (Student's t test).
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antisense oligodeoxynucleotides was significantly lowerthan
that of control or sense oligodeoxynucleotides-treated cells
in response to any of the three growth factors (Fig. 1, A-C),
whereas that of NB4 (Fig. 1 D) or HL-60 cells (Fig. 1 E)
was unchanged compared to controls. As in the case ofcolony
formation from primary cells, inhibition ofM07 cell prolifer-
ation was dose dependent: lower concentrations (80 + 40
+ 40 jig/ml) of GAP antisense oligodeoxynucleotides in-
duced only about 40-50% inhibition of cell growth and the
effect was almost undetectable at concentrations of 40 + 20
+ 20 Ftg/ml.
EffectofGAPAntisense Oligodeoxynucleotides on theProlifer-
ation of bcr/abl-dependent CML-BC Cells. The growth of
Philadelphia' BV173 cells and of primary cells from CML-
BC patients used in these studies was highly dependent on
bcr/ablexpression, as demonstrated by the fact that exposure
of these cells to antisense oligodeoxynucleotides designed
against the specific breakpoint junction identified in each
sample results not only in downregulation of bcr-ablmRNA
expression, but also in complete inhibition of growth, and
even death, ofBV173 cells in liquid culture, and in significant
inhibition (61.5-100%) of colony formation from marrow
cells of CML-BC patients (UPN 1-5) in semisolid culture
(data not shown). In agreement with reports by others (43),
we observed a physical association of p210briabi with p120
GAP in these cells (Fig. 2), suggesting the possibility of a
functional link between these two proteins. To test this pos-
sibility, we examined the effect ofGAP antisense oligodeoxy-
nucleotides (160 + 80 + 80 lAg/ml) on proliferation ofBV173
cells. The cell growth was completely inhibited and GAP,
but not a-actin mRNA levels, were simultaneously down-
regulated, as detected by RT-PCR (Fig. 3). This effect was
dose dependent (data not shown). Moreover, GAP antisense,
but not sense, oligomers caused selective downregulation of
the levels of p120 GAP protein by 50-67% (data from two
independent experiments), but not those of HSP (Fig. 3),
Colonies Inducer Control
Number
Sense
of colonies/plate
Antisense Percent inhibition
CFU-GM IL-3 245.3 ± 31.9" 210.3 ± 38.4 91 .5 ± 34.0 56.5 (p <0.001)t
GM-CSF 222.0 ± 24.2 186.2 ± 10.6 91 .0 ± 7.1 51 .5 (p <0.001)
BFU-E IL-3 + Epo 194.5 ± 12.0 179.2 ± 17.5 58 .2 ± 15.5 67.5 (p <0.001)
SCF + Epo 73.0 ± 8.3 70.8 ± 16.2 40.3 ± 4.7 43.1 (p <0.001)
CFU-Meg IL-6 + IL-3 + Epo 23 .4 ± 4.9 20.8±3.7 8.4±2.4 59.6 (p<0.001)as detected by Western blotting, further supporting that the
effects of GAP antisense treatment described above are se-
quence specific.
CML-BC primary cells (UPN 1-5) were incubated with
GAP antisense oligodeoxynucleotides under the same condi-
tions as normal bonemarrow cells, except that in some cases
exogenous IL-3 was omitted from the cultures (Table 3) . In
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Figure 1 .
￿
Effect ofGAP oligodeoxynucleotides
on the proliferation of growth factor-dependent
M07 cells and ofgrowth factor-independent NB4
and H1,60 cells, and on the expression ofGAP
mRNA.GAP sense (lane S) or antisense (lane AS)
oligodeoxynucleotides (160 + 80 + 80 Ag/ml)
were added toM07 cells growing in the presence
of Ib3 (A), GM-CSF (B), SCF (C), NB4 (D), and
HL60 (E) cells growing in the absence ofhuman
growth factors. Control (lane C) groups were left
untreated . Viable cells, as determined by trypan
blue exclusion, were counted on days 4, 6, and 8
of culture. GAP and O-actin mRNA expression
was determined after 72-hculture. TotalRNA was
isolated and divided into two aliquots that were
separately amplified withGAP and (3-actin-specific
primers usingRTPCR . TheresultingcDNAs were
hybridized to specific 32P-end labeled probes as de-
scribed in Materials and Methods . Data are repre-
sentative ofat least three independent experiments.
one experiment performed on cells from patient UPN 1,
CD34+ MNC were used . GAP sense oligodeoxynucleotides
did not influence significantly the growth ofCML-BC pri-
mary cells compared to that of control untreated cells
(-3.5-11.0% inhibition) . Both IL-3-dependent and IL-3-in-
dependent CML-BC colony formation was significantly in-
hibited by treatment withGAP antisense oligodeoxynucleo-Figure 2 .
￿
Association of p210k~l bi and p120 GAP. Anti-GAP or
nonimmune (M) control sera were used for immunoprecipitation from
the indicated cell lines or patient primary cells. The immunoprecipitates
were resolved in 7.5% SDS-PAGE and transferred to nitrocellulose mem-
brane . Anti-abl antibody was used for Western blot analysis of the trans-
ferred proteins .
tides (55.7-87.4% and 87.3-91.0% inhibition, respectively)
in comparison to sense-treated groups . A 3-d incubation of
CML-BC cells (UPN 1) in the presence of GAP antisense
oligodeoxynucleotides (160 + 80 + 80 Wg/ml) caused down-
regulation of GAP but not of (3-actin mRNA expression
(Fig . 4) .
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Effect ofGAP Oligomers on p120GAP Expression in Growth
Factor-stimulatedM07 Cells. To examine the effect ofgrowth
factors on GAP mRNA levels, M07 cells were incubated in
serum-free medium for 12 h, after which IL-3 was added and
total RNA and postnuclear cell lysates were prepared from
an equal number of cells 0, 4, 8, 12, 24, and 48 h later. In-
creased expression ofGAP mRNA, and protein levels (4-9-
fold in three experiments), were detected by RT-PCR and
Western blotting, respectively, starting 4 h after stimulation
(Fig . 5, A and B) . 0-actinmRNA and HSP levels remained
constant throughout the culture period . To determine whether
theGAP antisense could inhibit IL-3-induced p120GAP over-
expression, M07 cells were serum starved and IL-3 stimu-
lated in the presence of GAP oligomers (160 + 80 + 80
hg/ml) . Postnuclear cell lysates were collected from 106 cells
after 48-h stimulation. GAP antisense, but not sense, oligomers
inhibited IL-3-inducible GAPmRNA (data not shown) and
p120 GAP expression by 67-85% (data from three experi-
ments) in comparison to controls (Fig . 5 C) .
p21'°5 Activity after IL-3 Stimulation .
￿
We determined the
fraction of GTP-bound RAS in M07 cells stimulated with
IL-3 . Only 3.3% of the p21'° 5 was detected in the active
GTP-bound form inM07 cells incubated for 18 h in serum-
and growth factor-free medium . This fraction increased to
10.7% after 5-min incubation with IL-3 (Fig. 6 A) and re-
mained at levels (6 .7%) lower than this, but significantly
higher than those in control untreated cells, after 48-h cul-
ture in the presence of IL-3 (Fig. 6 A) .
GTPasepromoting Activity in M07 Cells after IL-3 Stimula-
tion. Because GTPase promoting activity is involved in
regulating the status of p21'°5 activation, we determined it
inM07 cells stimulated with IL-3 . 15 .6 ± 0.7, 24.2 ± 3 .7,
and 6.6 ± 4.4% ofp21- was in the GTP-bound form after
incubation with total cells lysate obtained from serum- and
growth factor-starved cells or cells obtained 5 min and 48 h
after IL-3 stimulation, respectively (Fig. 6 B) . Compared to
untreated cells, GTPase-promoting activity was inhibited 5
min after IL-3 stimulation, but was even higher at 48 h . As
Figure 3 .
￿
Effect of GAP oligodeoxynucleotides
on the proliferation and GAP mRNA expression
of bcr/abl-dependent BV173 cells . Growth ofBV173
cells and levels of GAP and i3-actin mRNA were
determined as described in Fig . 1 . The levels of
GAP protein and HSP 72/73 were analyzed by
Westernblotting in postnuclear cell lysates obtained
from cells after 72-h incubation with sense (S) or
antisense (AS) oligomers . Control (C) cells were
left untreated .Table 3.
￿
In Vitro CML-BC Cells Colony Formation in the Presence ofGAP Sense and Antisense Oligodeoxynucleotides
shown in Fig. 6 B inset, -45% of this activity was due to
p120 GAP, as revealed by performing the assay with GAP-
depleted lysates, the remaining activity was most likely due
to NF-1 as revealed by a 55% inhibition ofGTPase promoting
activity when the assay was performed in the presence of the
specific NF-1 inhibitor n-dodecyl-/3-D-mannoside .
Discussion
A powerful experimental approach to define the function
of a gene is to specifically inhibit its in vivo activity. Inmam-
malian cells, this can be accomplished with the antisense
strategy (44) . Using this approach to dissect the role of in-
dividual genes in signal transduction pathways, we observed
that the N-ras protooncogene is important in the growth of
normal human hemopoietic cells (27) . p21-, like other
GTP-binding proteins, is activated by the replacement ofGDP
by GTP, a process that is catalyzed by a guanine nucleo-
tide-releasing factor (16) . The active p21--GTP-bound form
is inactivated by an intrinsic GTPase activity that is catalyzed
by the COON-terminal domain ofGAP (45) . Increasing evi-
dence suggests that, in addition to its interaction with p21-
via the COOH-terminal domain, GAP also interacts with
phosphoproteins with tyrosine kinase activity such as the
Figure 4. Expression of GAP and
/3-actin mRNA in CMILBC cells (UPN
1) exposed toGAP oligodeoxynucleotides.
GAP and (3-actin mRNA levels were ana-
lyzed as described in Fig . 1 .
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Cells (105 A-T-MNC or, where indicated, 104 CD34' cells) were cultured in the presence or absence of IL-3 . Results are expressed as mean
from quadruplicate determination in two to four independent experiments .
t Inhibition of colony formation by GAP antisense oligodeoxynucleotides in comparison with sense-treated
nificance (Student's t test)-
t SD
groups . In parentheses, statistical sig-
Figure 5 .
￿
Expression ofGAP in I1,3-stimulated and oligodeoxynucle-
otide-treatedM07 cells. Cells were incubated with IL3(A and B) or 11,3
plus oligodeoxynucleotides (C) . TotalRNA and cell lysates were prepared
at the indicated times (hrs) . (A) RTPCR analysis of GAP and /3-actin
mRNA levels; (B and C) GAP protein andHSP 72/73 analysis . GAP pro-
tein expression was analyzedby Western blottingoftotal cell lysates using
anti-GAP serum (7.5%SDS-PAGE) . As control ofthe amount ofproteins
loaded per lane, the same filter was sequentially hybridized with anti-heat
shock protein (HSP 72/73)mAb. Densitometric measurements of thebands
were performed using an Ultro ScanXL (PharmaciaLKBBiotechnology)
apparatus .
Number of colonies/plate
Patient Inducer Control Sense Antisense Percent inhibition
UPN1 . IL-3 2,594.3 ± 261 .1' 2,496.0 ± 338.0 548 .5 ± 27.6 78.0 (p = 0.015)t
None 425 .7 ± 65.5 378.7 ± 6 .7 34 .0 ± 7.8 91 .0 (P <0.001)
UPN1/CD34" IL-3 265 .5 ± 23 .3 233.0 ± 36.8 28.0 ± 4.2 87.4 (p = 0.006)
UPN2 IL-3 1,778.0 ± 76 .4 1,512.8 ± 280.5 322.0 ± 5.7 78.7 (p = 0.005)
None 81 .5 ± 4.9 74.8±6 .3 9.5±0.7 87.3 (p<0.001)
UPN3 IL-3 198 .5 ± 12 .7 191.0 ± 7 .1 85 .0 ± 11.3 55.7 (p = 0.008)
UPN4 IL-3 1,129.0 ± 76 .4 1,168 .8 ± 124 .7 183.3 ± 34.6 83.7(p <0.001)
None 1,144.5 ± 170.4 960.3 ± 90.7 93.5 ± 2.1 90.3 (p <0.001)
UPN5 IL-3 27.0 ± 5.7 23.0 ± 4.2 4.0 ± 1 .4 82.67 (p = 0.027)tivity which impairs p21- signal-transducing ability) and as
signal transducer (linking p21- with tyrosine kinases) (52) .
The observation that induction of gene expression by GAP
SH2-SH3 domains depends on p21- activity (53) suggests
that p21--GTP induces conformational changes in GAP
which allow the SH2-SH3 domains to function .
To assess the functional requirement of GAP as a signal
transducer in normal and leukemic cells, we examined the
proliferation and colony-forming ability of these cells in the
presence ofGAP antisense oligodeoxynucleotides . Colony for-
mation by myeloid, erythroid, and megakaryocytic progen-
itors isolated from normal bone marrow cells (A-T-MNC
or CD34' cells) required GAP expression as did the growth
of the IL-3-dependent AML M07 cell line, of the Phila-
delphia' bcr/abl tyrosine kinase-dependent BV173 line, and
of CML primary cells . Because proliferation of the growth
factor-independent NB-4 and HL-60 cell lines is not affected
by downregulation ofGAP expression resulting from treat-
ment with antisense oligodeoxynucleotides, it appears that
GAP expression is required for proliferation in cells that are
growth factor-dependent or, as in the case of Philadelphia'
cells, when the oncogenic activation (formation of bcr-abl
genes) replaces growth factor requirements.
The growth and differentiation of hematopoietic progen-
itors induced by several growth factors (IL-3, GM-CSF, SCF,
and Epo) is accompanied by activation of p21- (9, 10, 54)
and phosphorylation of several target proteins (7, 55) . Bcr/abl
tyrosine kinase activates p21- (15), induces protein phos-
phorylation (55, 56), and is required for proliferation and
survival ofCML cells (57, 58) . Thus, it is conceivable that
GAP joins p21'°t (via its COOH terminus) and tyrosine ki-
nases (via its NH2 terminus) in the signal transduction
pathway, while maintaining its ability to convert p21- to
the inactive GDP-bound form, thus terminating the signal-
transducing stimulus. By inhibitingGAP expression, the link
between p21--GTP and tyrosine kinases may have been dis-
rupted .
Because the levels ofGAP expression appeared to be im-
portant in determining its effect on cell growth (59), we ex-
amined the expression ofGAP after growth factor stimula-
tion . Our experiments show that IL-3 upregulates GAP
mRNA as well as protein levels. A similarphenomenon was
observed also in CD34' bone marrow cells after stimula-
tion with IL-3, GM-CSF or SCF (data not shown) . Inhibi-
tion ofgrowth factor-stimulated cellular proliferation byGAP
antisense oligomers correlates with their ability to block the
growth factor-induced GAP overexpression, which strongly
suggests that increased levels ofGAP expression could be im-
portant for cell growth . The increase ofGAP protein level
correlated well with higher GTPase promoting activity in
M07 cells(45% GAP dependent, 55% NF-1 dependent) after
long-term (48 h) stimulation with IL-3 . In contrast, short-
term (5 min) stimulation induced a decrease of this activity.
PDGF and EGF receptors, src, bcr-abl, p190, p62, and p56kk,
￿
Similar short-term changes in GTPase promoting activity were
via two SH2 domains in the NH2-terminal region (43,
￿
observed in cells stimulated with Epo (54) and EGF (56) .
46-50) and with cytoskeleton via oneSH3 domain (51) . Those
￿
The changes in GTPase promoting activity in lysates of
observations led to the hypothesis that GAP can function both
￿
IL-3-stimulatedM07 cells were partially in agreement with
as signal terminator (catalysis ofp21- intrinsic GTPase ac-
￿
the p21- GTP-GDP status. The p21--GTP-bound fraction
Figure 6.
￿
Activation ofp21- and GTPase promoting activity in 11,3-
stimulated M07 cells. Serum and growth factor-starved cells were left
unstimulated or were stimulated with 11,3 for 5min or 48 h . Activation
status of p21- (A) and GTPase promoting activity (B) were examined
at each time point . Bars represent values (mean ± SD) from three (A)
and two (B) independent experiments (each performed in duplicate) of
GTPbound p21- over total (GTP- and GDPbound) . P values (Student's
t test) indicate the level of statistical significance compared to control un-
treated group. The percentage of p120GAP and NF-1 dependent GTPase
promoting activity (B, inset) was established after incubation of p21-GTP
complex (lane 1) with total cell lysate from M07 cells stimulated with
11,3 for 48 h (lane 2) from which the p120 GAP or NF-1 activity were
removed by immunoprecipitation with anti-GAP serum (lane 3) or incu-
bation in the presence of n-dodecyl a-D-mannoside (lane 4) .
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and was still -twofold higher after long-term (48 h) incu-
bation in the presence of the cytokine. The status of p21-
activation is the result of stimulatory (guanine-nucleotide
releasing factor [GNRF]) andinhibitory (GAP, NF-1) con-
trol mechanisms. Shortly after cytokine stimulation, p21ra5
becomes activated because of the increased GNRF activity
(16) and the decreased GTPase promoting activity (54, and
our observations). By comparison, in M07 cells exposedfor
a much longer time (48 h) to IL-3, the levels of active GTP-
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